Aclaris Therapeutics, Inc.

ACRS

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001557746

SEC filings (opens in a new tab)

No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Aclaris Therapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026 All holders in Q4 2025

13F holders of ACRS: Q4 2025 compared with Q1 2026
Measure	Q4 2025	Of which not filed for Q1 2026	Q1 2026	Change
Holders	122	3	136	+17
Shares	83.7M	8.21M	109.2M	+33.7M (+44.6%)
Value	$252.1M	$24.7M	$409.4M	+$182.1M (+80.1%)

3 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (33)

Institutions that held Aclaris Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to ACRS in Q1 2026
Institution	Shares	Value	% of portfolio
Deep Track Capital, LP	9,345,000	$35.0M	0.72%
Ra Capital Management, L.P.	6,804,072	$25.5M	0.27%
Vanguard Capital Management LLC	5,167,469	$19.4M	0.00%
Frazier Life Sciences Management, L.P.	4,925,374	$18.5M	0.48%
Balyasny Asset Management LLC	3,361,328	$12.6M	0.02%
Kalehua Capital Management LLC	1,832,365	$6.87M	4.86%
Braidwell LP	1,699,116	$6.37M	0.21%
Vanguard Portfolio Management LLC	1,656,066	$6.21M	0.00%
Vanguard Fiduciary Trust Co	628,859	$2.36M	0.00%
Monashee Investment Management LLC	500,000	$1.88M	1.02%
MPM Oncology Impact Management LP	391,918	$1.47M	0.11%
Superstring Capital Management LP	366,490	$1.37M	0.98%
SEI Investments Co	217,154	$814.3K	0.00%
Mackenzie Financial Corp	213,405	$800.3K	0.00%
Verdad Advisers, LP	197,042	$738.9K	0.83%
EAM Investors, LLC	178,378	$668.9K	0.08%
Vanguard Global Advisers, LLC	68,793	$258.0K	0.00%
CenterBook Partners LP	66,598	$249.7K	0.01%
EntryPoint Capital, LLC	33,007	$123.8K	0.04%
Diversified Trust Co	29,455	$110.5K	0.00%
Engineers Gate Manager LP	18,294	$68.6K	0.00%
JustInvest LLC	17,558	$65.8K	0.00%
ExodusPoint Capital Management, LP	16,895	$63.4K	0.00%
Hudson Bay Capital Management LP	16,820	$63.1K	0.00%
STRS Ohio	16,000	$60.0K	0.00%
Prudential Financial Inc	13,380	$50.2K	0.00%
M&T Bank Corp	10,088	$37.8K	0.00%
Zurcher Kantonalbank (Zurich Cantonalbank)	5,006	$18.8K	0.00%
MBM Wealth Consultants, LLC	3,198	$12.0K	0.00%
Parallel Advisors, LLC	357	$1.34K	0.00%
Allworth Financial LP	49	$184	0.00%
Root Financial Partners, LLC	27	$101	0.00%
MAI Capital Management	1	$4	0.00%

Sold out (16)

Institutions that held Aclaris Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of ACRS in Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Ameriprise Financial Inc	318,426	$958.5K
Two Sigma Advisers, LP	255,400	$768.8K
Seven Fleet Capital Management LP	107,419	$323.3K
Point72 Asset Management, L.P.	87,175	$262.4K
Man Group plc	42,435	$127.7K
Valeo Financial Advisors, LLC	27,540	$82.9K
Jane Street Group, LLC	27,216	$81.9K
Axq Capital, LP	24,186	$72.8K
Persistent Asset Partners Ltd	22,259	$67.0K
Mariner, LLC	16,670	$50.2K
Group One Trading, L.P.	12,433	$37.4K
R Squared Ltd	12,408	$37.3K
Amalgamated Bank	2,883	$9.00K
Advisor Group Holdings, Inc.	730	$2.20K
Quattro Advisors LLC	372	$1.12K
SRS Capital Advisors, Inc.	19	$57

Not filed for Q1 2026 yet (3)

Institutions that held Aclaris Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ACRS in Q4 2025 that haven't filed for Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Vanguard Group Inc	6,502,080	$19.6M
Kotler Kevin	1,705,929	$5.13M
Motiv8 Investments LLC	1,000	$3.00K